FIND-CKD Phase 3: Finerenone Slows Kidney Decline in Non-Diabetic CKD

Finerenone is a selective, nonsteroidal mineralocorticoid receptor antagonist (MRA) that reduces aldosterone-driven inflammation and fibrosis in the kidney. Unlike the older steroidal MRAs — spironolactone and eplerenone — it has minimal off-target sex hormone effects and a much lower rate of hyperkalemia. The FIDELIO-DKD and FIGARO-DKD trials established its role in diabetic kidney disease, reducing the risk of eGFR decline and cardiovascular events in patients with CKD and type 2 diabetes. Now the FIND-CKD trial extends that evidence to a population that had been entirely excluded from prior registrational studies: people with CKD but without diabetes.[1]

FIND-CKD enrolled more than 1,500 adults with non-diabetic CKD encompassing a wide range of underlying etiologies — IgA nephropathy, focal segmental glomerulosclerosis, hypertensive nephrosclerosis, polycystic kidney disease, and others. Participants were already on maximally tolerated renin-angiotensin system (RAS) inhibition. The trial met its primary endpoint: finerenone significantly slowed the annual rate of eGFR decline compared with placebo. The composite of kidney failure, 40% eGFR decline, and cardiovascular death was also reduced. Hyperkalemia requiring treatment was more common with finerenone, consistent with prior MRA experience, but rates of treatment discontinuation were low.[1]

The key clinical implication is that finerenone's benefits in CKD are not diabetes-specific. Aldosterone-driven inflammation and fibrosis operate in the kidney regardless of whether the patient has diabetes; the FIND-CKD data confirm that blocking the mineralocorticoid receptor slows this process across a heterogeneous non-diabetic CKD population. This effectively positions finerenone alongside SGLT2 inhibitors as a second disease-modifying agent for non-diabetic CKD.[1, 2]

Clinical Context

The case for finerenone in CKD was built on two landmark trials in diabetic CKD. The FIDELIO-DKD trial (2020, NEJM) randomized 5,734 patients with type 2 diabetes and CKD to finerenone or placebo on top of maximally tolerated RAS inhibition; it reduced the composite kidney outcome (40% eGFR decline, kidney failure, or renal death) by 18% and cardiovascular events by 14%.[2] FIGARO-DKD (2021, NEJM), enrolling a somewhat less advanced CKD population with greater emphasis on cardiovascular outcomes, demonstrated a 13% reduction in the composite of cardiovascular death and non-fatal cardiovascular events.[3] Both trials excluded patients without type 2 diabetes, leaving a major unmet need: non-diabetic CKD affects millions of patients and shares the same aldosterone-driven fibrotic mechanism.

Non-diabetic CKD encompasses a heterogeneous set of diseases — IgA nephropathy, FSGS, hypertensive nephrosclerosis, polycystic kidney disease, and others — but they share a final common pathway of progressive glomerulosclerosis and tubulointerstitial fibrosis mediated in part by mineralocorticoid receptor (MR) activation. The DAPA-CKD trial (2020, NEJM) established dapagliflozin as the first SGLT2 inhibitor to reduce CKD progression in non-diabetic patients — a signal that kidney protection does not require a diabetic milieu.[4] FIND-CKD asked the same question for MR antagonism, providing the first large-scale randomized evidence that finerenone's nephroprotective effects generalize beyond the diabetic CKD population that defined its regulatory approvals.[1]

Why It Matters Clinically

The emerging picture in CKD management is one of layered protection. RAS inhibition reduces glomerular hypertension. SGLT2 inhibitors reduce tubuloglomerular feedback and lower intraglomerular pressure via hemodynamic and metabolic mechanisms. Finerenone addresses the inflammatory and fibrotic arm of CKD progression. These mechanisms are complementary, and combination use is where the field is heading. The ongoing CONFIDENCE trial is testing finerenone plus dapagliflozin versus either agent alone in diabetic CKD — preliminary data suggest additive benefits with manageable hyperkalemia rates.[2]

Limitations

The FIND-CKD population was heterogeneous — the magnitude of benefit may differ substantially across underlying CKD etiologies. Hyperkalemia monitoring adds clinical burden and cost. The trial was presented at ERA 2026 and peer-reviewed data are awaited; full methodology, statistical analysis plan, and subgroup analyses will be important to review before regulatory submissions are complete. Generalizability across different healthcare systems with varying nephrology follow-up capacity requires evaluation.